Hitachi (NYSE:HIT) and Redlen Technologies said they inked a deal to co-develop a component used in photon-counting computed tomography devices.
The Japanese conglomerate’s Hitachi Medical subsidiary and Redlen are slated to develop a direct-conversion semiconductor X-ray detector module, a necessary component for PCCT systems, the companies said.
Saanichton, British Columbia-based Redlen makes high-resolution cadmium zinc telluride semiconductor radiation detectors. The pact calls for the duo to jointly develop the data acquisition technology to process data from the sensors, which is an order of magnitude higher than that of conventional CT systems. Hitachi will have exclusive rights to the technology, the companies said.
“We are excited to partner with Hitachi, 1 of the original pioneers of medical CT technology, to pursue the enormous potential for advancement in medical CT that photon counting semiconductor sensors offer,” president & CEO Glenn Bindley said in prepared remarks.
“PCCT is a promising next generation device which achieves radiation exposure reduction, high functionality and high degree of precision. It is expected to broaden the field of application. I hope this agreement will provide opportunities for us to further contribute to healthcare innovation,” added Hitachi healthcare president & CEO Masaya Watanabe.
The post Hitachi, Redlen ink development deal for next-gen CT component appeared first on MassDevice.